Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF.

Mills R, Mathur A, Nicol LM, Walker JJ, Przybylski AA, Mackinnon AC, Howie SEM, Wallace WAH, Dransfield I, Hirani N.

J Immunol Res. 2019 Apr 11;2019:1845128. doi: 10.1155/2019/1845128. eCollection 2019.

2.

CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.

Cai M, Bonella F, He X, Sixt SU, Sarria R, Guzman J, Costabel U.

Respir Med. 2013 Sep;107(9):1444-52. doi: 10.1016/j.rmed.2013.06.004. Epub 2013 Jul 5.

3.

Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.

Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, Gibson KF, Kaminski N, Banga G, Oddis CV, Pilewski JM, Sciurba FC, Donahoe M, Zhang Y, Duncan SR.

Am J Respir Crit Care Med. 2013 Apr 1;187(7):768-75. doi: 10.1164/rccm.201203-0506OC.

4.

Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies.

Fahim A, Chong MC, Crooks MG, Hart SP.

Lung. 2012 Aug;190(4):451-8. doi: 10.1007/s00408-012-9390-z. Epub 2012 May 16.

PMID:
22584870
5.

Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.

Kim Y, Lee YJ, Cho YJ, Yoon HI, Lee JH, Lee CT, Park JS.

Tohoku J Exp Med. 2018 Nov;246(3):147-153. doi: 10.1620/tjem.246.147.

6.

Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.

Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M.

Eur Respir J. 1999 Aug;14(2):376-82.

8.

Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.

Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Müller-Quernheim J.

Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):762-8.

PMID:
9517588
9.
10.

[The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].

Zhu C, Zhao YB, Kong LF, Li ZH, Kang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):93-7. doi: 10.3760/cma.j.issn.1001-0939.2016.02.004. Chinese.

PMID:
26879611
11.

Mononuclear phagocytes and airway epithelial cells: novel sources of matrix metalloproteinase-8 (MMP-8) in patients with idiopathic pulmonary fibrosis.

Craig VJ, Polverino F, Laucho-Contreras ME, Shi Y, Liu Y, Osorio JC, Tesfaigzi Y, Pinto-Plata V, Gochuico BR, Rosas IO, Owen CA.

PLoS One. 2014 May 14;9(5):e97485. doi: 10.1371/journal.pone.0097485. eCollection 2014.

12.

BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.

Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, Patrizio V, Bobbio-Pallavicini F, Pozzi E, Montecucco C.

Sarcoidosis Vasc Diffuse Lung Dis. 2004 Jun;21(2):111-8.

PMID:
15281432
13.

Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis.

Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC.

Respir Med. 2011 Jan;105(1):106-13. doi: 10.1016/j.rmed.2010.09.012.

14.

MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.

Korthagen NM, Nagtegaal MM, van Moorsel CH, Kazemier KM, van den Bosch JM, Grutters JC.

Clin Exp Immunol. 2010 Aug;161(2):342-7. doi: 10.1111/j.1365-2249.2010.04181.x. Epub 2010 Jun 9.

15.

S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.

Hara A, Sakamoto N, Ishimatsu Y, Kakugawa T, Nakashima S, Hara S, Adachi M, Fujita H, Mukae H, Kohno S.

Respir Med. 2012 Apr;106(4):571-80. doi: 10.1016/j.rmed.2011.12.010. Epub 2011 Dec 30.

16.

Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses.

Harlow L, Gochuico BR, Rosas IO, Doyle TJ, Osorio JC, Travers TS, Camacho CC, Oddis CV, Ascherman DP.

Clin Immunol. 2014 Nov;155(1):60-70. doi: 10.1016/j.clim.2014.08.004. Epub 2014 Aug 19.

17.

Macrophage inflammatory protein-1 alpha expression in interstitial lung disease.

Standiford TJ, Rolfe MW, Kunkel SL, Lynch JP 3rd, Burdick MD, Gilbert AR, Orringer MB, Whyte RI, Strieter RM.

J Immunol. 1993 Sep 1;151(5):2852-63.

PMID:
8360496
18.

The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.

Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M.

Respir Med. 2017 Jun;127:57-64. doi: 10.1016/j.rmed.2017.04.007. Epub 2017 Apr 15.

19.

Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis.

Huang H, Wang Y, Jiang C, Lang L, Wang H, Chen Y, Zhao Y, Xu Z.

Pulm Pharmacol Ther. 2014 Jun;28(1):49-52. doi: 10.1016/j.pupt.2013.10.004. Epub 2013 Nov 7.

PMID:
24211813
20.

Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.

White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, Moore BB, Cheng L, Doyle TJ, Villalba J, Dellaripa PF, Rosas IO, Kurtis JD, Martinez FJ.

Am J Respir Crit Care Med. 2016 Nov 15;194(10):1242-1251.

Supplemental Content

Support Center